Vor Biopharma Inc. Lease, Cost
Vor Biopharma Inc. (VOR) reported Lease, Cost of $225.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-11
- Vor Biopharma Inc. lease, cost for the quarter ending 2026-06-30 was $225.00K, a 98.38% decline year-over-year.
- Vor Biopharma Inc. lease, cost for the quarter ending 2026-03-31 was $217.00K, a 91.85% decline year-over-year.
- Vor Biopharma Inc. lease, cost for the quarter ending 2025-12-31 was $254.00K, a 90.64% decline year-over-year.
- Vor Biopharma Inc. lease, cost for the quarter ending 2025-09-30 was $140.00K, a 94.68% decline year-over-year.
- Vor Biopharma Inc. lease, cost for fiscal 2025 was $16.91M, a 61.76% increase from fiscal 2024.
- Vor Biopharma Inc. lease, cost for fiscal 2024 was $10.46M, a 0.36% increase from fiscal 2023.
- Vor Biopharma Inc. lease, cost for fiscal 2023 was $10.42M, a 26.56% increase from fiscal 2022.
- Vor Biopharma Inc. lease, cost for fiscal 2022 was $8.23M, a 97.53% increase from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $225.00K 10-Q · filed 2026-08-11 | $442.00K 10-Q · filed 2026-08-11 | $696.00K derived: sum of 3 quarters · filed 2026-08-11 | $836.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $217.00K 10-Q · filed 2026-05-13 | $471.00K derived: sum of 2 quarters · filed 2026-05-13 | $611.00K derived: sum of 3 quarters · filed 2026-05-13 | $14.47M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $254.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $394.00K derived: sum of 2 quarters · filed 2026-03-30 | $14.25M derived: sum of 3 quarters · filed 2026-08-11 | $16.91M 10-K · filed 2026-03-30 |
| 2025-09-30 | $140.00K 10-Q · filed 2025-11-13 | $14.00M derived: sum of 2 quarters · filed 2026-08-11 | $16.66M 10-Q · filed 2025-11-13 | $19.38M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $13.86M 10-Q · filed 2026-08-11 | $16.52M 10-Q · filed 2026-08-11 | $19.23M derived: sum of 3 quarters · filed 2026-08-11 | $21.87M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $2.66M 10-Q · filed 2026-05-13 | $5.38M derived: sum of 2 quarters · filed 2026-05-13 | $8.01M derived: sum of 3 quarters · filed 2026-05-13 | $10.64M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $2.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $5.35M derived: sum of 2 quarters · filed 2026-03-30 | $7.98M derived: sum of 3 quarters · filed 2026-03-30 | $10.46M 10-K · filed 2026-03-30 |
| 2024-09-30 | $2.63M 10-Q · filed 2025-11-13 | $5.26M derived: sum of 2 quarters · filed 2025-11-13 | $7.74M 10-Q · filed 2025-11-13 | $10.39M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $2.63M 10-Q · filed 2025-08-12 | $5.11M 10-Q · filed 2025-08-12 | $7.76M derived: sum of 3 quarters · filed 2025-08-12 | $10.37M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $2.48M 10-Q · filed 2025-05-14 | $5.13M derived: sum of 2 quarters · filed 2025-05-14 | $7.74M derived: sum of 3 quarters · filed 2025-05-14 | $10.35M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $2.65M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $5.26M derived: sum of 2 quarters · filed 2025-03-20 | $7.87M derived: sum of 3 quarters · filed 2025-03-20 | $10.42M 10-K · filed 2025-03-20 |
| 2023-09-30 | $2.61M 10-Q · filed 2024-11-07 | $5.22M derived: sum of 2 quarters · filed 2024-11-07 | $7.77M 10-Q · filed 2024-11-07 | $10.29M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $2.61M 10-Q · filed 2024-08-08 | $5.16M 10-Q · filed 2024-08-08 | $7.68M derived: sum of 3 quarters · filed 2024-08-08 | $10.24M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $2.55M 10-Q · filed 2024-05-09 | $5.07M derived: sum of 2 quarters · filed 2024-05-09 | $7.63M derived: sum of 3 quarters · filed 2024-05-09 | $9.52M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $2.52M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $5.08M derived: sum of 2 quarters · filed 2024-03-20 | $6.97M derived: sum of 3 quarters · filed 2024-03-20 | $8.23M 10-K · filed 2024-03-20 |
| 2022-09-30 | $2.56M 10-Q · filed 2023-11-07 | $4.45M derived: sum of 2 quarters · filed 2023-11-07 | $5.71M 10-Q · filed 2023-11-07 | $6.79M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $1.89M 10-Q · filed 2023-08-10 | $3.15M 10-Q · filed 2023-08-10 | $4.23M derived: sum of 3 quarters · filed 2023-08-10 | $5.33M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $1.26M 10-Q · filed 2023-05-11 | $2.34M derived: sum of 2 quarters · filed 2023-05-11 | $3.44M derived: sum of 3 quarters · filed 2023-05-11 | $4.51M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $2.18M derived: sum of 2 quarters · filed 2023-03-23 | $3.25M derived: sum of 3 quarters · filed 2023-03-23 | $4.17M 10-K · filed 2023-03-23 |
| 2021-09-30 | $1.10M 10-Q · filed 2022-11-10 | $2.17M derived: sum of 2 quarters · filed 2022-11-10 | $3.09M 10-Q · filed 2022-11-10 | $3.98M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $1.07M 10-Q · filed 2022-08-11 | $1.99M 10-Q · filed 2022-08-11 | $2.88M derived: sum of 3 quarters · filed 2022-08-11 | $3.70M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $921.00K 10-Q · filed 2022-05-12 | $1.81M derived: sum of 2 quarters · filed 2022-05-12 | $2.63M derived: sum of 3 quarters · filed 2022-05-12 | $3.04M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $893.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $1.71M derived: sum of 2 quarters · filed 2022-03-14 | $2.12M derived: sum of 3 quarters · filed 2022-03-14 | $2.32M 10-K · filed 2022-03-14 |
| 2020-09-30 | $816.00K 10-Q · filed 2021-11-10 | $1.23M derived: sum of 2 quarters · filed 2021-11-10 | $1.43M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $414.00K 10-Q · filed 2021-08-09 | $615.00K 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $201.00K 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |